Korea's Hanlim, Daewoong and Pacific Pharmas Prepare Launch For Modified Actonel
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean local pharmas Hanlim Pharm, Daewoong Pharmaceutical and Pacific Pharma are gearing up to sell an incrementally modified version of Actonel (risendronate), which was originally developed by Sanofi-Aventis and has been sold in Korea by local firm Handok Pharmaceuticals